Market Closed - Toronto S.E. 01:46:18 2024-04-23 pm EDT 5-day change 1st Jan Change
0.075 CAD 0.00% Intraday chart for MedMira Inc. -6.25% -31.82%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
MedMira Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024 CI
Samsung Pay to stop working with Russia's Mir payment system from April 3 RE
MedMira Says Received Canadian Patent for its Quantitative Diagnostic System MT
MedMira Brief: Says Received Canadian Patent for its Quantitative Diagnostic System MT
MedMira's Fiscal Q1 Loss Widens, Revenue Drops MT
MedMira Inc. Reports Earnings Results for the First Quarter Ended October 31, 2023 CI
U.S. FDA Approves MedMira's Advanced Reveal G4 Rapid HIV-1/2 Antibody Test CI
MedMira Inc. Reports Earnings Results for the Full Year Ended July 31, 2023 CI
Medmira Inc. Provides Update on Its Progress to Achieve Regulatory Approval in Canada and the USA for Its Infectious Disease Rapid Tests CI
MedMira's Fiscal Q3 Loss Widens, Revenue Falls MT
MedMira Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2023 CI
MedMira Falls Near 17% As Widens Q2 Net Loss YOY MT
MedMira Widens Q2 Net Loss YOY MT
MedMira Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2023 CI
MedMira Inc. Provides an Update on Its Progress to Achieve Regulatory Approval in Canada for Its Reveal TP Antibody Test CI
MedMira Enters into Partnership with Maternova for USA and Latin America MT
Maternova and MedMira Enter Distribution Agreement to Market Rapid Diagnostics for HIV, Syphilis and Hepatitis CI
MedMira Provides Progress Update MT
MedMira Reports Wider Fiscal Q1 Loss, Lower Revenue MT
MedMira Introduces New Product In Direct Response to Rise of Respiratory Syncytial Virus Cases Globally MT
MedMira Inc. Introduces VYRA TriDemic CI
MedMira Inc. Reports Earnings Results for the First Quarter Ended October 31, 2022 CI
MedMira Inc. Auditor Raises 'Going Concern' Doubt CI
MedMira Inc. Reports Earnings Results for the Full Year Ended July 31, 2022 CI
MedMira Inc. Appoints Sam Ratnam as Director of Scientific & Regulatory Affairs CI
Chart MedMira Inc.
More charts
MedMira Inc. is a Canada-based biotechnology company. The Company, through its subsidiaries, is engaged in the business of research, development and manufacturing of rapid diagnostics and technologies. The Company invests in research in order to maintain and expand its position in the global diagnostics market. Its research is focused on specific areas of the broader diagnostics market, namely the rapid, point-of-care, and in vitro sectors. The Company is the developer and owner of Rapid Vertical Flow (RVF) Technology. The Company's rapid test applications built on RVF Technology provide hospitals, labs, clinics and individuals with instant diagnosis for diseases such as Human Immunodeficiency Virus (HIV), Syphilis and hepatitis C in just three easy steps. The Company's tests are sold under the Reveal, Multiplo and Miriad brands in global markets. The Company's manufacturing facilities are located in Halifax, Nova Scotia, Canada.
More about the company
  1. Stock Market
  2. Equities
  3. MIR Stock
  4. News MedMira Inc.
  5. MedMira Provides Update on New In Vitro Diagnostic Medical Devices Regulation (IVDR) in the European Market